0001193125-22-242389 | 6-K | XBRL Viewer

Print Document View Excel Document

Cover Page	6 Months Ended
Cover Page	Jun. 30, 2022
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Registrant Name	Pharvaris N.V.
Entity Central Index Key	0001830487
Current Fiscal Year End Date	--12-31

Condensed consolidated statements of profit or loss and other comprehensive income or loss - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Profit or loss [abstract]
Research and development expenses	€ (13,721,637)	€ (8,060,599)	€ (27,236,126)	€ (16,132,053)
General and administrative expenses	(7,660,133)	(4,664,726)	(13,525,138)	(8,436,415)
Total operating expenses	(21,381,770)	(12,725,325)	(40,761,264)	(24,568,468)
Finance income/(expense)	11,501,804	(2,474,483)	14,892,983	3,344,373
Loss before income tax	(9,879,966)	(15,199,808)	(25,868,281)	(21,224,095)
Income taxes	(2,741,102)	(2,965)	(2,779,817)	(21,554)
Loss for the period	(12,621,068)	(15,202,773)	(28,648,098)	(21,245,649)
Other comprehensive income/(Loss)
Exchange gains arising on translation of foreign operations	(89,091)	426	(80,411)	1,675
Total comprehensive loss attributable to:
Equity holders of the Company	€ (12,710,159)	€ (15,202,347)	€ (28,728,509)	€ (21,243,974)
Loss per share attributable to the equity holders of the Company during the periods
Basic and diluted loss per share	€ (0.38)	€ (0.46)	€ (0.86)	€ (0.77)

Condensed consolidated statements of financial position - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Non-current assets
Property, plant and equipment	€ 141,846	€ 108,099
Right of use assets	210,714	243,250
Current assets
Deferred tax assets	99,852	172,052
Receivables	331,928	700,079
Other current assets	4,575,567	1,513,452
Cash and cash equivalents	201,383,087	209,353,132
Total assets	206,742,994	212,090,064
Equity
Share capital	4,051,916	3,978,226
Share premium	288,100,008	278,742,900
Other reserves	14,713,625	9,774,416
Currency translation reserve	(54,483)	25,928
Accumulated loss	(116,237,411)	(87,568,401)
Total equity	190,573,655	204,953,069
Long term liabilities
Non-current lease liability	102,093	150,752
Current liabilities
Trade and other payables	4,168,955	2,490,572
Accrued liabilities	8,981,038	4,270,082
Current lease liability	110,772	99,432
Current tax liability	2,806,481	126,157
Total liabilities	16,169,339	7,136,995
Total equity and liabilities	€ 206,742,994	€ 212,090,064

Condensed consolidated statements of changes in equity - EUR (€)	Total	Share capital [member]	Share premium [member]	Other reserves [member]	Currency translation reserve [member]	Accumulated losses [member]
Beginning balance at Dec. 31, 2020	€ 95,785,829	€ 235,693	€ 138,034,580	€ 1,979,875	€ (4,365)	€ (44,459,954)
Net loss	(21,245,649)					(21,245,649)
Increase in par value		2,592,621	(2,592,621)
Issue of share capital	157,155,899	1,141,329	156,014,570
Transaction costs on issue of shares	(13,154,360)		(13,154,360)
Currency translation reserve	1,675				1,675
Shares issued upon exercise of RSUs	(265,255)	1,709		(35,161)		(231,803)
Share-based payments	3,869,348			3,869,348
Shares issued upon exercise of options	80,920	4,080	133,360	(56,520)
Ending balance at Jun. 30, 2021	222,228,407	3,975,432	278,435,529	5,757,542	(2,690)	(65,937,406)
Beginning balance at Dec. 31, 2021	204,953,069	3,978,226	278,742,900	9,774,416	25,928	(87,568,401)
Net loss	(28,648,098)					(28,648,098)
Issue of share capital	9,535,473	70,572	9,464,901
Transaction costs on issue of shares	(307,710)		(307,710)
Currency translation reserve	(80,411)				(80,411)
Share-based payments	5,089,777			5,089,777
Settlement of share-based payments	31,555	3,118	199,917	(150,568)		(20,912)
Ending balance at Jun. 30, 2022	€ 190,573,655	€ 4,051,916	€ 288,100,008	€ 14,713,625	€ (54,483)	€ (116,237,411)

Condensed consolidated statements of cash flows - EUR (€)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Loss before tax	€ (25,868,281)	€ (21,224,095)
Non-cash adjustments to reconcile loss before tax to net cash flows from operations:
Share-based payment expense	5,089,777	3,869,348
Depreciation expense	68,195	15,048
Net foreign exchange (gain)/loss	(14,971,998)	(3,503,986)
Finance costs	79,016	159,613
Changes in working capital:
Decrease/(Increase) in receivables	368,151	(143,187)
(Increase) in other current assets	(2,563,219)	(3,919,580)
Increase in trade and other payables	1,678,383	2,367,811
Increase in accrued liabilities	4,609,866	481,628
Paid interest	(58,463)	(134,418)
Income taxes paid	0	(27,095)
Net cash flows used in operating activities	(31,568,574)	(22,058,913)
Investing activities
Purchase of property, plant and equipment	(49,739)	(33,554)
Net cash flows used in investing activities	(49,739)	(33,554)
Financing activities
Proceeds from issue of shares	9,587,940	157,236,819
Transaction costs	(727,308)	(12,925,547)
Decrease in financial liability	(37,319)	(5,012)
Net cash flows provided by financing activities	8,823,313	144,306,260
Net increase (decrease) in cash and cash equivalents	(22,794,999)	122,213,793
Cash and cash equivalents at the beginning of the period	209,353,132	98,628,871
Effect of exchange rate changes	14,824,955	3,475,076
Cash and cash equivalents at the end of the period	€ 201,383,087	€ 224,317,740

Corporate and Group information

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Corporate and Group information

1. Corporate and Group information

This section provides general corporate and group information about Pharvaris N.V. and its subsidiaries.

1.1 Corporate information

Pharvaris N.V. was incorporated on September 30, 2015 and is based in Leiden, the Netherlands.

The address of its registered office is J.H. Oortweg 21, Leiden. The Company’s registered office is located at J.H. Oortweg 21, Leiden. It has been registered at the Chamber of Commerce under file number 64239411.

The unaudited condensed consolidated interim financial statements of Pharvaris N.V. (the “Company” or “Pharvaris”) and its subsidiaries (collectively, “The Group”) as of June 30, 2022 and December 31, 2021, and for the three and six months ended June 30, 2022 and 2021 were authorized for issue in accordance with a resolution of the directors on

September 12

, 2022.

1.2 Group information

Subsidiaries

The unaudited condensed consolidated interim financial statements of the Group include:


	Legal seat	Country of incorporation	% of equity interest as June 30,
Name	Legal seat	Country of incorporation	2022			2021
Pharvaris Holdings B.V.	Leiden	The Netherlands		100	%		100	%
Pharvaris Netherlands B.V.	Leiden	The Netherlands		100	%		100	%
Pharvaris GmbH	Zug	Switzerland		100	%		100	%
Pharvaris, Inc.	Delaware	United States of America		100	%		100	%

The ultimate parent company

The ultimate parent company of the Group is Pharvaris N.V.

Summary of significant accounting policies

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of significant accounting policies

2. Summary of significant accounting policies

2.1 Basis of preparation

The unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2021 (“last annual financial statements”). These unaudited condensed consolidated interim financial statements do not include all the information required for a complete set of financial statements prepared in accordance with IFRS as issued by the IASB.

However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last annual financial statements.

The unaudited condensed consolidated interim financial statements have been prepared on a historical cost basis. Unless otherwise stated, the unaudited condensed consolidated interim financial statements are presented in euros and all values are rounded to the nearest EUR (€), except per share amounts.

Revision of prior period loss per share

In the period ended June 30, 2022, the Company determined that it had incorrectly computed the weighted average number of ordinary shares outstanding used as denominator in calculating its basic and diluted loss per share in previously issued interim financial statements. This error had no impact to the Company’s operating expenses, or loss for the period, and had no impact to the Company’s consolidated statements of financial position, consolidated statements of changes in equity or consolidated statements of cash flows.

The Company assessed the materiality of these errors on the previously issued condensed consolidated interim financial statements and concluded that the errors were not material to any period presented. The impact of the revision of the previously issued interim financial statements is as follows:

As reported vs revised ‘weighted average number of shares’:


	As reported weighted average number of shares (Quarterly)		As reported weighted average number of shares (YTD)		Revision of weighted average number of shares (Quarterly)		Revision of weighted average number of shares (YTD)
Q1 2021		9,104,630		9,104,630		22,104,888		22,104,888
Q2 2021		16,154,350		16,154,350		33,126,351		27,646,066
Q3 2021		23,282,105		23,282,105		33,128,593		29,493,657
Q1 2022		33,135,821		33,135,821		33,151,892		33,151,892

As reported vs revised ‘basic and diluted loss per share’:


	As reported basic and diluted loss per share (Quarterly)			As reported basic and diluted loss per share (YTD)			Revision of basic and diluted loss per share (Quarterly)			Revision of basic and diluted loss per share (YTD)
Q1 2021		(0.66	)		(0.66	)		(0.27	)		(0.27	)
Q2 2021		(0.94	)		(1.32	)		(0.46	)		(0.77	)
Q3 2021		(0.39	)		(1.31	)		(0.28	)		(1.03	)
Q1 2022		(0.48	)		(0.48	)		(0.48	)		(0.48	)

2.2 Going concern

Pharvaris is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. These therapies will need to go through clinical development trials to achieve regulatory approval for commercialization. Therefore, Pharvaris is incurring annual research and development and other operating costs and has no revenues to date (as is typical in the biotech industry for development stage and early commercial stage companies). As such, Pharvaris anticipates

on-going

negative operating cash flows for several years before the company has a product candidate ready for commercialization, if at all. This makes the Group dependent on external capital sources, debt capital and equity capital. The Group is currently fully financed by equity capital.

As of June 30, 2022 and December 31, 2021 the Group had cash of €201.4 million and €209.4 million, respectively. The Group incurred net losses of €28.6 million in the six months ended June 30, 2022 and €21.2 million in the same period in 2021 and negative operating cash flows of €31.6 million and €22.1 million in the six months ended June 30, 2022 and the six months ended June 30, 2021 respectively.

The Group does not expect positive operating cash flows in the foreseeable future and remains dependent on additional financing to fund its research and development expenses, general and administrative expenses and financing costs. The Group believes that the available cash balances are sufficient to execute the Group’s operating plan and strategies and to meet the anticipated working capital requirements and settle all expected liabilities for at least twelve months from the issuance date of these unaudited condensed consolidated interim financial statements. Accordingly, the unaudited condensed consolidated interim financial statements have been prepared on a going concern basis.

The future viability of the Group is dependent on its ability to raise additional capital to finance its operations. The Group will need to finance its operations through public or private securities offerings, debt financings or other sources, which may include licensing, collaborations or other strategic transactions or arrangements. Although the Group has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Group, if at all. If the Group is unable to obtain funding, the Group could be forced to delay, reduce, or eliminate some or all of its research and development programs for product candidates, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Group may be unable to continue operations.

Impact of

COVID-19

The Group has taken steps to identify and mitigate the adverse effects and risks to it as a result of the pandemic. The Group has modified its business practices, including implementing work from home arrangements for employees able to perform their duties remotely and practicing safe social distancing in our operations. The Group expects to continue to take actions as may be required or recommended by government authorities or in the best interests of its employees and business partners. While the impact of

COVID-19

on the Group’s operations and financial performance has so far been limited, the extent to which

COVID-19

may impact its financial condition or results of operations in the future is uncertain. For instance, the ongoing spread of variants of the

COVID-19

virus may continue to interrupt, or delay, the Group’s clinical trial activities, regulatory reviews, manufacturing activities and supply chain.

The

COVID-19

outbreak delayed, and may continue to delay, enrollment in the Group’s clinical trials due to prioritization of hospital resources towards the outbreak or other factors, and some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay our ability to conduct clinical trials or release clinical trial results and could delay our ability to obtain regulatory approvals and commercialize our product candidates. In addition, even with the Group’s distributed operations, employee vaccinations and its observation of social distancing measures, there remains the possibility that key personnel may become ill or are otherwise unable to work, which could affect the Group’s operations.

Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA, which may delay the development of the Company’s product candidates. The spread of an infectious disease, including

COVID-19

may also result in the inability of the Group’s suppliers to deliver components or raw materials, and the inability of the Group’s CDMOs to provide supplies of our product candidates for the Group’s planned clinical trials, on a timely basis or at all. Further, an infectious disease. including

COVID-19

may also impact the ability of the Group’s CROs, including nonclinical CROs, to provide services to support the Group’s clinical program. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread of an infectious disease. Such events may result in a period of business disruption, and in reduced operations, or doctors and medical providers may be unwilling to participate in the Group’s clinical trials, any of which could materially affect the Group’s business, financial condition and results of operations.

The extent to which the

COVID-19

pandemic impacts the Group’s business will depend on future developments, which are uncertain and cannot be predicted, including amongst other things, new information which may emerge concerning the severity of the

COVID-19

pandemic and the actions to contain

COVID-19

or treat its impact, including among other things the effectiveness and outreach of

COVID-19

vaccines. If the Group is unable to meet its milestones it might jeopardize our funding opportunities.

2.3 Use of judgements and estimates

In preparing these unaudited condensed consolidated interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

2.4 Change in significant accounting policies

The accounting policies applied in these unaudited condensed consolidated interim financial statements are the same as those applied in the consolidated financial statements for the year ended December 31, 2021.

Research and development expenses

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Research and development expenses

3. Research and development expenses


	For the three months ended June 30						For the six months ended June 30
	2022			2021			2022			2021
	€			€			€			€
Personnel expenses (Note 5)		(3,061,036	)		(1,759,669	)		(5,590,207	)		(3,768,165	)
Clinical expenses		(7,175,545	)		(3,496,223	)		(13,741,610	)		(6,761,928	)
Nonclinical expenses		(1,016,793	)		(1,181,660	)		(1,832,918	)		(2,143,713	)
Manufacturing costs		(2,419,143	)		(1,601,980	)		(5,883,668	)		(2,920,172	)
License costs		—			—			—			(500,000	)
Intellectual Property costs		(49,120	)		(21,067	)		(187,723	)		(38,075	)

		(13,721,637	)		(8,060,599	)		(27,236,126	)		(16,132,053	)

Development expenses are currently not capitalized but are recorded in the unaudited condensed consolidated statements of profit or loss and other comprehensive income because the recognition criteria for capitalization are not met.

Clinical expenses include costs of conducting and managing our sponsored clinical trials, including clinical investigator cost, costs of clinical sites, and costs for CRO’s assisting with our clinical development programs.

Nonclinical expenses include costs of our outsourced discovery, preclinical and nonclinical development studies.

Manufacturing expenses include costs related to manufacturing of active pharmaceutical ingredients and manufacturing of the products used in our clinical trials and research and development activities

License costs during the period ended June 30, 2021 consist of a milestone payment of €500,000 which was paid to AnalytiCon upon commencement of Phase 2 development.

General and administrative expenses

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

General and administrative expenses

4. General and administrative expenses


	For the three months ended June 30						For the six months ended June 30
	2022			2021			2022			2021
	€			€			€			€
Personnel expenses (Note 5)		(3,825,151	)		(1,795,721	)		(6,270,034	)		(3,036,786	)
Consulting fees		(254,899	)		(161,559	)		(432,811	)		(390,872	)
Professional fees		(911,170	)		(324,793	)		(1,795,170	)		(1,132,706	)
Accounting, tax and auditing fees		(290,159	)		(648,626	)		(594,657	)		(1,086,756	)
Facilities, communication & office expenses		(1,618,732	)		(1,510,566	)		(3,246,830	)		(2,462,147	)
Travel expenses		(260,446	)		(2,563	)		(404,200	)		(3,357	)
Other expenses		(499,576	)		(220,898	)		(781,436	)		(323,791	)

		(7,660,133	)		(4,664,726	)		(13,525,138	)		(8,436,415	)

In 2021 the Group entered into a number of lease arrangements, which were assessed to be short-term leases (with a lease term of 12 months equaling its

non-cancellable

period).

Depreciation expense in the six months of 2022 was €68,195 (2021: €15,048), which related to property, plant and equipment and leases and is included in the ‘Other expenses’ line. For the second quarter of 2022 a total of €35,345 (2021: €11,987) depreciation charge was included in ‘Other expenses’.

Personnel expenses

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Personnel expenses

5. Personnel expenses


	For the three months ended June 30						For the six months ended June 30
	2022			2021			2022			2021
	€			€			€			€
Wages and salaries		(3,279,593	)		(1,606,969	)		(5,845,176	)		(2,618,645	)
Pension charges		(177,185	)		(51,327	)		(355,729	)		(81,289	)
Other social security charges		(286,570	)		(124,356	)		(569,559	)		(235,669	)
Share-based payments		(3,142,839	)		(1,772,738	)		(5,089,777	)		(3,869,348	)

		(6,886,187	)		(3,555,390	)		(11,860,241	)		(6,804,951	)

The average number of staff (in FTEs) employed by the Group in the six months ended June 30, 2022 was 47 (2021: 17).

Finance income/(expense)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Finance income/(expense)

6. Finance income/(expense)


	For the three months ended June 30						For the six months ended June 30
	2022			2021			2022			2021
	€			€			€			€
Foreign exchange differences		11,535,811			(2,401,910	)		14,971,998			3,503,986
Interest expenses over bank balances		(33,457	)		(69,552	)		(78,517	)		(151,764	)
Other finance expenses		(550	)		(3,021	)		(499	)		(7,849	)

		11,501,804			(2,474,483	)		14,892,983			3,344,373

Income taxes

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Income taxes

7. Income taxes

Income taxes are accounted for in line with IAS 34. The interim period is considered part of a larger financial year, where the income tax is recognized in each interim period based on the best estimate of the weighted average annual income tax rate expected for the full financial year. The estimated tax expenses are determined based on a full year basis and subsequently allocated using the expected full year effective tax rate. The discrete items are recognized in full in the interim period in which they emerge. In the total interim tax charge, no distinction is made between current and deferred tax expenses/income.


	For the three months ended June 30						For the six months ended June 30

	2022			2021			2022			2021

	€			€			€			€
Income tax expense		(2,741,102	)		(2,965	)		(2,779,817	)		(21,554	)

		(2,741,102	)		(2,965	)		(2,779,817	)		(21,554	)

The total tax expenses over the six months ended June 30, 2022

principally

relates to the Dutch fiscal unity in the Netherlands, which reported an estimated tax expense of €2.7

million

during the period. During the period, the Dutch fiscal unity reported a taxable income of approximately €17.4

million

which was mainly driven by foreign exchange gains. Of the total taxable income, an amount of

€

7.0

million

was set off by the utilization of the accumulated losses carried forward (which were previously not recognized), resulting in a net taxable profit of €10.4

million

Reconciliation of income tax benefit at statutory tax rate and the income tax expense as reported in the unaudited condensed consolidated statement of profit or loss and other comprehensive income is as follows:


	For the three months ended June 30						For the six months ended June 30

	2022			2021			2022			2021

	€			€			€			€
Income/(loss) before tax		(9,879,966	)		(15,199,807	)		(25,868,281	)		(21,224,095	)
Income tax at statutory income tax rate in The Netherlands (25.8%)		2,549,031			3,799,952			6,674,016			5,306,024
Effect of tax rates in other countries		(3,211,414	)		(1,160,468	)		(6,017,458	)		(3,171,956	)
Temporary differences for which no deferred tax assets/liabilities have been recognized		—			(184,629	)		—			(162,580	)
Nondeductible expenses		(84,694	)		(96,125	)		(190,060	)		(587	)
Current period losses for which no deferred tax asset has been recognized		(1,994,025	)		(2,361,695	)		(3,246,315	)		(1,992,455	)

Income tax expense		(2,741,102	)		(2,965	)		(2,779,817	)		(21,554	)

Income tax expense is recognized based on management’s estimate of the weighted average effective annual income tax rate expected for the full financial year, bearing in mind the impact of

non-discrete

and discrete items. Non-discrete items in the income tax expense are recognized based on management’s estimate of the weighted average effective annual income tax rate expected for the full financial year. Discrete items in the income tax expense are recognized for the applicable statutory tax rate.

The (estimated) average annual tax rate used for the six months ended June 30, 2022

10.7

compared to

0.1

for the six months ended June 30, 2021. The estimated effective tax rate includes significant discrete tax effects relating to the tax impact (after utilization of DTAs previously not recognized) on foreign exchange gains. As foreign exchange results cannot be reliably forecasted, the effective tax rate at year end may deviate from the currently reflected estimated effective tax rate.

The Current

period

losses for which no deferred tax asset has been recognized consists of the expense related to the losses in Switzerland, offset by the benefit from the utilization of previously unrecognized losses carried forward in the Netherlands.

The differences in the overseas tax rates are due to the lower tax rate in Switzerland and the higher tax rate in the USA compared to the statutory income tax rate in the Netherlands.

Pharvaris N.V. is the head of the fiscal unity including Pharvaris Netherlands B.V. and Pharvaris Holdings B.V.

Deferred tax

Deferred taxes have been recognized to the extent that management concludes that there is sufficient probability as per IAS 12 that there will be future taxable profits available in the foreseeable future against which the unused tax losses can be utilized.

Deferred tax assets relating to losses carried forward have not been recognized, and deferred tax assets on deductible temporary differences in excess of deferred tax liabilities on taxable temporary differences have neither been recognized in the unaudited condensed consolidated statement of profit or loss and other comprehensive income nor in the unaudited condensed consolidated statement of financial position.

Property, plant and equipment

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Property, plant and equipment

8. Property, plant and equipment


	Notes		Office equipment

			€
Balance at January 1, 2022				108,099
Additions				49,739
Depreciation expense		4		(15,992	)

Balance at June 30, 2022				141,846

Balance at June 30, 2022
Cost				184,443
Accumulated depreciation				(42,597	)

Net book amount				141,846

During the six months ended June 30, 2022, the Group acquired assets with a cost of €49,739 (December 31, 2021: €78,251). The acquisitions during the six months ended June 30, 2022 and the year ended December 31, 2021 were related to equipment, tools and installations.

Leases

6 Months Ended

Jun. 30, 2022

Disclosure Of Leases [Abstract]

Leases

9. Leases

The following table provides information about the Group’s

right-of-use

assets:


	June 30, 2022			December 31, 2021

	€			€
Balance at January 1		243,250			—
Addition		—			301,965
Depreciation charges		(52,203	)		(58,715	)
Impact of transaction of foreign currency		19,667			—

Balance at June 30, 2021		210,714			243,250

The following table provides information about the Group’s lease liabilities:


	June 30, 2022			December 31, 2021

	€			€
Office lease		(212,865	)		(250,184	)
Total lease liability		(212,865	)		(250,184	)
Current portion		(110,772	)		(99,432	)
Non-current portion		(102,093	)		(150,752	)

The lease agreement started on June 1, 2021 and has a lease term of three years. The average incremental borrowing rate applied to the lease liabilities was 3.12% during the six months ended June 30, 2022 (

2021

1.5

%).

Cash

outflows

related to leases during the six months ended June 30, 2022 and 2021 were €38,428 and €5,012, respectively.

Receivables

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Receivables

10. Receivables


	June 30, 2022		December 31, 2021

	€		€
Trade Receivables		7,920		8,451
VAT receivables		324,008		691,628

		331,928		700,079

Other current assets

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Other current assets

11. Other current assets


	June 30, 2022		December 31, 2021

	€		€
Prepayments		3,991,672		1,507,753
Other assets		583,895		5,699

		4,575,567		1,513,452

Prepayments mainly relate to prepaid insurance,

sign-on

bonus to personnel, prepaid R&D expenses and rent.

Other assets mainly consist of deferred transaction costs related to Group’s

in-process

equity financing (refer to note 13). The company defers the transaction costs related to any

in-process

financing. Upon recognition of the equity instruments, the related transaction costs are deducted from share premium.

Cash and cash equivalents	6 Months Ended
Cash and cash equivalents	Jun. 30, 2022
Text Block [Abstract]
Cash and cash equivalents	12. Cash and cash equivalents Cash and cash equivalents comprise of cash in bank and are not subject to any restriction.

Equity

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Equity

13. Equity

On June 30, 2022, the Company’s authorized share capital amounted to €14,100,000 divided into 58,750,000 ordinary shares and 58,750,000 preferred shares, each with a nominal value of €0.12. As at June 30, 2022, a total number of ordinary shares issued was 33,765,967 (2021: 33,151,881). On June 30, 2022, the issued share capital totaled to €4,051,916 (2021: €3,975,432

In March 2022, the Company filed a Form

F-3

Registration Statement and prospectus with the Securities and Exchange Commission relating to an

at-the-market

program providing for the sales from time to time of up to $75,000,000 of its ordinary shares pursuant to a Sales Agreement with SVB

Securities

LLC. During the six months ended June 30, 2022, the Company sold a total of 588,100 ordinary shares in two different transactions under the sales agreement generating total net proceeds of $9,698,504 (€9.2

million

), after deducting $299,954 (€308,000), which was payable to SVB

Securities

as commission in respect of such sales.

On February 5, 2021, the Company became public by listing its ordinary shares on the Nasdaq Stock Exchange. On the same date all Preferred shares A, Preferred shares B and Preferred shares C were automatically converted to ordinary shares and 9,511,075 ordinary shares were issued. Together with the issuance of the ordinary shares, the par value of each ordinary share was increased from €0.01 to €0.12.

Ordinary shares hold the right to one vote per share.

Issued shares


	June 30, 2022		December 31, 2021
	Number of shares		Number of shares
Ordinary shares		33,765,967		33,151,881

		33,765,967		33,151,881

Trade and other payables

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Trade and other payables

14. Trade and other payables


	June 30, 2022		December 31, 2021
	€		€
Trade payables		3,681,792		2,125,511
Tax and social security liabilities		487,163		365,061

		4,168,955		2,490,572

Accrued liabilities

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Accrued liabilities

15. Accrued liabilities


	June 30, 2022		December 31, 2021
	€		€
Consulting, professional and audit liability		1,002,291		786,116
Clinical accrued liabilities		1,405,000		386,328
Manufacturing accrued liabilities		4,487,910		1,231,514
Pre-clinical accrued liabilities		99,000		398,468
Personnel related accruals		1,941,900		1,459,162
Other accrued liabilities		44,937		8,494

		8,981,038		4,270,082

Risk management activities	6 Months Ended
Risk management activities	Jun. 30, 2022
Text Block [Abstract]
Risk management activities	16. Risk management activities The Group’s risk management activities are the same as disclosed in note 17 of the consolidated financial statements for the year ended December 31, 2021.

Fair values	6 Months Ended
Fair values	Jun. 30, 2022
Text Block [Abstract]
Fair values	17. Fair values Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

Share-based payments

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Share-based payments

18. Share-based payments

In 2016, the Company implemented an Equity Incentive Plan (the “Plan”) in order to advance the interests of the Company’s shareholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with performance-based incentives that are intended to better align the interests of such persons with those of the Company’s shareholders. This plan has been superseded by the 2021 long term incentive plan (“LTIP”).

Set out below is an overview of changes in the Stock Options and Restricted Stock Units (“RSUs”) during the six months ended June 30, 2022


	Stock Options					RSUs

	Outstanding options			Weighted average exercise price		Outstanding RSUs

Outstanding January 1, 2022		2,470,295		€	9.18		259,714
Granted		742,500		€	16.12		345,196
Exercised		(22,045	)	€	2.38		(5,190	)
Forfeited		—			—		(903	)

Outstanding June 30, 2022		3,190,750		€	10.84		598,817

On January 1, 2022, a total of 70,000 stock options were granted to members of the Board of Directors with an exercise price of $14.39 per share with a final exercise date of December 31, 2031 unless forfeited or exercised on an earlier date. 25% of the aggregate number of share options shall vest on December 31, 2022 and thereafter 1/48th of the aggregate number of share options shall vest on each subsequent monthly anniversary of the vesting commencement date until either the option is fully vested

or the option holders’ continuous service terminates.

On April 1, 2022, a total of 552,500 stock options were granted to members of the Board of Directors and key management with an exercise price of $18.14 per share with a final exercise date of March 31, 2032 unless forfeited or exercised on an earlier date. 25% of the aggregate number of share options shall vest on March 31, 2023 and thereafter 1/48th of the aggregate number of share options shall vest on each subsequent monthly anniversary of the vesting commencement date until either the option is fully vested

or the option holders’ continuous service terminates.

On June 1, 2022, a total of 120,000 stock options were granted to members

key management with an exercise price of $17.98 per share with a final exercise date of May 31, 2032 unless forfeited or exercised on an earlier date. 25% of the aggregate number of share options shall vest on May 31, 2023 and thereafter 1/48th of the aggregate number of share options shall vest on each subsequent monthly anniversary of the vesting commencement date until either the option is fully vested

or the option holders’ continuous service terminates.

During the six months ended June 30, 2022 a total of 345,196 RSUs were granted to employees that joined the Group in the same period and existing employees. The RSUs shall vest equally over a four-year period on each of the four anniversaries of the vesting start date until either the RSUs are fully vested or the RSUs holders’ continuous service terminates.

The fair value of the RSUs is determined based on the share value per ordinary share at the grant date (or at the first trading day after the grant date if the Nasdaq Stock Exchange is not open on this date). The grant dates were January 1, 2022, February 1, 2022, March 1, 2022, April 1, 2022, May 1, 2022 and June 1, 2022. The share closing price was $16.41, $17.00, $18.47, $18.14, $17.10, and $17.98 at January 3, 2022, February 1, 2022, March 1, 2022, April 1, 2022, May 2, 2022 and June 1, 2022, respectively.

For the six months ended June 30, 2022, the Group recognized €5,089,777 of share-based payment expense in the unaudited condensed consolidated statement of income or loss and other comprehensive income (six months ended June 30, 2021: €3,869,347). For the three months ended June 30, 2022, the Group recognized €3,142,839 of share-based payment expense in the unaudited condensed consolidated statement of income or loss and other comprehensive income (three months ended June 30: €1,772,738).

As of June 30, 2022, a total number of 1,287,099 stock options are exercisable (June 30, 2021: 337,667).

The inputs and outputs used in the measurement of the fair value per option at each grant/ measurement date using the Black-Scholes formula (including the related number of options and the fair value of the options) were as follows:


	June 1, 2022			April 1, 2022			January 1, 2022

Number of options		120,000			552,500			70,000
Fair value of the options	€	11.83		€	11.50		€	9.10
Fair value of the ordinary shares	€	16.78		€	16.41		€	12.67
Exercise price	€	16.78		€	16.41		€	12.67
Expected volatility (%)		80	%		80	%		85	%
Expected life (years)		6.1			6.1			6.1
Risk-free interest rate (%)		3.0	%		2.6	%		1.4	%
Expected dividend yield		—			—			—

Expected volatility is based on an evaluation of the historical volatilities of comparable listed biotech-companies over the most recent historical period that commensurate with the expected option life. The expected life is based on Management’s best estimate of when the options will be exercised. The risk-free interest rate is based on the yield on US Government bonds, with tenure equal to the expected life. The expected dividend yield is zero considering the stage of the Group.

Basic and diluted loss per share

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Basic and diluted loss per share

19. Basic and diluted loss per share

Basic and diluted loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of issued and outstanding ordinary shares during the three and six months ended June 30, 2022 and June 30, 2021.

All of the Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share attributable to ordinary stockholders as the effect of including them would be antidilutive.


	For the three months ended June 30,						For the six months ended June 30,

	2022			2021 (*)			2022			2021 (*)

	€			€			€			€
Loss attributable to equity holders of the Company		(12,710,159	)		(15,202,347	)		(28,728,509	)		(21,243,974	)
Weighted average number of ordinary shares outstanding		33,582,171			33,126,351			33,368,220			27,646,066
Basic and diluted loss per share		(0.38	)		(0.46	)		(0.86	)		(0.77	)

(*) This has been revised. Refer to Note 2.1.

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2022
Text Block [Abstract]
Commitments and Contingencies	20. Commitments and Contingencies Claims There are no material claims known to management related to the activities of the Group. Commitments The Group’s contractual obligations and commitments as of June 30, 2022 amounted to €16 million, (December 31, 2021: €19.5 million) primarily related to research and development commitments. The Group had no contingent liabilities and no contingent assets as at June 30, 2022 and at June 30, 2021, respectively.

Related parties

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Related parties

21. Related parties

Note 1.2 provides information about the Group’s structure, including details of the subsidiaries and the holding company. The following provides the total amount of transactions that have been entered into with related parties for the relevant financial period.

Key management personnel compensation


	For the three months ended June 30,				For the six months ended June 30,

	2022		2021		2022		2021

	€		€		€		€
Short term employee benefits		771,241		894,878		1,520,406		1,436,106
Post employee benefits		33,177		6,622		78,559		22,099
Share-based payments		954,796		825,074		2,175,098		2,122,736

Total		1,759,214		1,726,574		3,774,063		3,580,941

A total number of 445,000 stock options and 14,216 RSUs are granted to key management during the six months ended June 30, 2022. Refer to note 18 for disclosures on the share-based payments.

The Group engages several management entities for the purpose of providing key management services to the Group. The aggregate value of transactions related to key management personnel, or entities which they control were €538,744 and €974,125 in the six months ended June 30, 2022 and 2021, respectively.

The outstanding balances payable to key management personnel, or entities which they control, as per June 30, 2022 and December 31, 2021 were €417,760 and €1,157,029, respectively.

Events after the reporting period	6 Months Ended
Events after the reporting period	Jun. 30, 2022
Text Block [Abstract]
Events after the reporting period	22. Events after the reporting period On August 22, 2022, the Company announced that the U.S. Food and Drug Administration (the “FDA”) had verbally informed it that, based on its review of nonclinical data, the agency is placing a clinical hold on the clinical trials of PHA121 in the United States (the “clinical hold”). The FDA indicated it will provide a formal clinical hold letter to Pharvaris within approximately 30 days following the verbal notice. On September 12, 2022, the Company announced that it has received formal clinical hold letters from the FDA. The FDA requested that the Company conduct an additional long-term rodent toxicology study and update the Investigator’s Brochure. The letters stated that the nonclinical observations are unlikely due to B2 receptor antagonism, the primary mechanism of action of PHA121. The Company plans to request a Type A meeting with the FDA to discuss on-demand and prophylactic proposals to address the clinical holds. In the RAPIDe-1 study, subsequent to the clinical hold in the U.S., the Company continues to evaluate PHVS416 for HAE attacks in patients enrolled outside the U.S. Given the current dataset of evaluable attacks, the Company anticipates announcing top-line data for the RAPIDe-1 study in the fourth quarter of 2022. The Company is working with country-specific regulatory authorities regarding the ongoing CHAPTER-1 Phase 2 study of PHVS416 for the prophylactic treatment of HAE attacks. The Company has notified country-specific regulatory authorities in Canada, Europe, Israel, and the UK of the U.S. clinical hold. When the Company has more clarity regarding the impact of the U.S. clinical hold and additional feedback from global regulatory authorities, the Company will provide guidance on the timing of announcing top-line data for the CHAPTER-1 trial.

Summary of significant accounting policies (Policies)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Basis of preparation

2.1 Basis of preparation

Revision of prior period loss per share

As reported vs revised ‘weighted average number of shares’:


	As reported weighted average number of shares (Quarterly)		As reported weighted average number of shares (YTD)		Revision of weighted average number of shares (Quarterly)		Revision of weighted average number of shares (YTD)
Q1 2021		9,104,630		9,104,630		22,104,888		22,104,888
Q2 2021		16,154,350		16,154,350		33,126,351		27,646,066
Q3 2021		23,282,105		23,282,105		33,128,593		29,493,657
Q1 2022		33,135,821		33,135,821		33,151,892		33,151,892

As reported vs revised ‘basic and diluted loss per share’:


	As reported basic and diluted loss per share (Quarterly)			As reported basic and diluted loss per share (YTD)			Revision of basic and diluted loss per share (Quarterly)			Revision of basic and diluted loss per share (YTD)
Q1 2021		(0.66	)		(0.66	)		(0.27	)		(0.27	)
Q2 2021		(0.94	)		(1.32	)		(0.46	)		(0.77	)
Q3 2021		(0.39	)		(1.31	)		(0.28	)		(1.03	)
Q1 2022		(0.48	)		(0.48	)		(0.48	)		(0.48	)

Going concern

2.2 Going concern

on-going

Impact of

COVID-19

on the Group’s operations and financial performance has so far been limited, the extent to which

COVID-19

may impact its financial condition or results of operations in the future is uncertain. For instance, the ongoing spread of variants of the

COVID-19

virus may continue to interrupt, or delay, the Group’s clinical trial activities, regulatory reviews, manufacturing activities and supply chain.

The

COVID-19

The extent to which the

COVID-19

pandemic and the actions to contain

COVID-19

or treat its impact, including among other things the effectiveness and outreach of

COVID-19

vaccines. If the Group is unable to meet its milestones it might jeopardize our funding opportunities.

Use of judgements and estimates

2.3 Use of judgements and estimates

Change in significant accounting policies

2.4 Change in significant accounting policies

Corporate and Group information (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Subsidiaries

The unaudited condensed consolidated interim financial statements of the Group include:


	Legal seat	Country of incorporation	% of equity interest as June 30,
Name	Legal seat	Country of incorporation	2022			2021
Pharvaris Holdings B.V.	Leiden	The Netherlands		100	%		100	%
Pharvaris Netherlands B.V.	Leiden	The Netherlands		100	%		100	%
Pharvaris GmbH	Zug	Switzerland		100	%		100	%
Pharvaris, Inc.	Delaware	United States of America		100	%		100	%

Summary of significant accounting policies (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of detailed information of net loss and average weighted number of shares

The impact of the revision of the previously issued interim financial statements is as follows:

As reported vs revised ‘weighted average number of shares’:


	As reported weighted average number of shares (Quarterly)		As reported weighted average number of shares (YTD)		Revision of weighted average number of shares (Quarterly)		Revision of weighted average number of shares (YTD)
Q1 2021		9,104,630		9,104,630		22,104,888		22,104,888
Q2 2021		16,154,350		16,154,350		33,126,351		27,646,066
Q3 2021		23,282,105		23,282,105		33,128,593		29,493,657
Q1 2022		33,135,821		33,135,821		33,151,892		33,151,892

Summary of prior period adjustment of earnings per share

As reported vs revised ‘basic and diluted loss per share’:


	As reported basic and diluted loss per share (Quarterly)			As reported basic and diluted loss per share (YTD)			Revision of basic and diluted loss per share (Quarterly)			Revision of basic and diluted loss per share (YTD)
Q1 2021		(0.66	)		(0.66	)		(0.27	)		(0.27	)
Q2 2021		(0.94	)		(1.32	)		(0.46	)		(0.77	)
Q3 2021		(0.39	)		(1.31	)		(0.28	)		(1.03	)
Q1 2022		(0.48	)		(0.48	)		(0.48	)		(0.48	)

Research and development expenses (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Schedule of Breakdown of Research and Development Expenses


	For the three months ended June 30						For the six months ended June 30
	2022			2021			2022			2021
	€			€			€			€
Personnel expenses (Note 5)		(3,061,036	)		(1,759,669	)		(5,590,207	)		(3,768,165	)
Clinical expenses		(7,175,545	)		(3,496,223	)		(13,741,610	)		(6,761,928	)
Nonclinical expenses		(1,016,793	)		(1,181,660	)		(1,832,918	)		(2,143,713	)
Manufacturing costs		(2,419,143	)		(1,601,980	)		(5,883,668	)		(2,920,172	)
License costs		—			—			—			(500,000	)
Intellectual Property costs		(49,120	)		(21,067	)		(187,723	)		(38,075	)

		(13,721,637	)		(8,060,599	)		(27,236,126	)		(16,132,053	)

General and administrative expenses (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Breakdown of General and Administrative Expenses


	For the three months ended June 30						For the six months ended June 30
	2022			2021			2022			2021
	€			€			€			€
Personnel expenses (Note 5)		(3,825,151	)		(1,795,721	)		(6,270,034	)		(3,036,786	)
Consulting fees		(254,899	)		(161,559	)		(432,811	)		(390,872	)
Professional fees		(911,170	)		(324,793	)		(1,795,170	)		(1,132,706	)
Accounting, tax and auditing fees		(290,159	)		(648,626	)		(594,657	)		(1,086,756	)
Facilities, communication & office expenses		(1,618,732	)		(1,510,566	)		(3,246,830	)		(2,462,147	)
Travel expenses		(260,446	)		(2,563	)		(404,200	)		(3,357	)
Other expenses		(499,576	)		(220,898	)		(781,436	)		(323,791	)

		(7,660,133	)		(4,664,726	)		(13,525,138	)		(8,436,415	)

Personnel expenses (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Personnel Expenses


	For the three months ended June 30						For the six months ended June 30
	2022			2021			2022			2021
	€			€			€			€
Wages and salaries		(3,279,593	)		(1,606,969	)		(5,845,176	)		(2,618,645	)
Pension charges		(177,185	)		(51,327	)		(355,729	)		(81,289	)
Other social security charges		(286,570	)		(124,356	)		(569,559	)		(235,669	)
Share-based payments		(3,142,839	)		(1,772,738	)		(5,089,777	)		(3,869,348	)

		(6,886,187	)		(3,555,390	)		(11,860,241	)		(6,804,951	)

Finance income/(expense) (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Financial Expenses


	For the three months ended June 30						For the six months ended June 30
	2022			2021			2022			2021
	€			€			€			€
Foreign exchange differences		11,535,811			(2,401,910	)		14,971,998			3,503,986
Interest expenses over bank balances		(33,457	)		(69,552	)		(78,517	)		(151,764	)
Other finance expenses		(550	)		(3,021	)		(499	)		(7,849	)

		11,501,804			(2,474,483	)		14,892,983			3,344,373

Income taxes (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Income Tax Expense


	For the three months ended June 30						For the six months ended June 30

	2022			2021			2022			2021

	€			€			€			€
Income tax expense		(2,741,102	)		(2,965	)		(2,779,817	)		(21,554	)

		(2,741,102	)		(2,965	)		(2,779,817	)		(21,554	)

Summary of Reconciliation of Income Tax Benefit And The Accounting Loss


	For the three months ended June 30						For the six months ended June 30

	2022			2021			2022			2021

	€			€			€			€
Income/(loss) before tax		(9,879,966	)		(15,199,807	)		(25,868,281	)		(21,224,095	)
Income tax at statutory income tax rate in The Netherlands (25.8%)		2,549,031			3,799,952			6,674,016			5,306,024
Effect of tax rates in other countries		(3,211,414	)		(1,160,468	)		(6,017,458	)		(3,171,956	)
Temporary differences for which no deferred tax assets/liabilities have been recognized		—			(184,629	)		—			(162,580	)
Nondeductible expenses		(84,694	)		(96,125	)		(190,060	)		(587	)
Current period losses for which no deferred tax asset has been recognized		(1,994,025	)		(2,361,695	)		(3,246,315	)		(1,992,455	)

Income tax expense		(2,741,102	)		(2,965	)		(2,779,817	)		(21,554	)

Property, plant and equipment (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Property, Plant and Equipment


	Notes		Office equipment

			€
Balance at January 1, 2022				108,099
Additions				49,739
Depreciation expense		4		(15,992	)

Balance at June 30, 2022				141,846

Balance at June 30, 2022
Cost				184,443
Accumulated depreciation				(42,597	)

Net book amount				141,846

Leases (Tables)

6 Months Ended

Jun. 30, 2022

Disclosure Of Leases [Abstract]

Summary of information about right of use assets

The following table provides information about the Group’s

right-of-use

assets:


	June 30, 2022			December 31, 2021

	€			€
Balance at January 1		243,250			—
Addition		—			301,965
Depreciation charges		(52,203	)		(58,715	)
Impact of transaction of foreign currency		19,667			—

Balance at June 30, 2021		210,714			243,250

Summary of information about lease lease liabilities

The following table provides information about the Group’s lease liabilities:


	June 30, 2022			December 31, 2021

	€			€
Office lease		(212,865	)		(250,184	)
Total lease liability		(212,865	)		(250,184	)
Current portion		(110,772	)		(99,432	)
Non-current portion		(102,093	)		(150,752	)

Receivables (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Receivables


	June 30, 2022		December 31, 2021

	€		€
Trade Receivables		7,920		8,451
VAT receivables		324,008		691,628

		331,928		700,079

Other current assets (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Other Current Assets


	June 30, 2022		December 31, 2021

	€		€
Prepayments		3,991,672		1,507,753
Other assets		583,895		5,699

		4,575,567		1,513,452

Equity (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Share Capital

Issued shares


	June 30, 2022		December 31, 2021
	Number of shares		Number of shares
Ordinary shares		33,765,967		33,151,881

		33,765,967		33,151,881

Trade and other payables (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Trade and Other Liabilities


	June 30, 2022		December 31, 2021
	€		€
Trade payables		3,681,792		2,125,511
Tax and social security liabilities		487,163		365,061

		4,168,955		2,490,572

Accrued liabilities (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Accrued Liabilities


	June 30, 2022		December 31, 2021
	€		€
Consulting, professional and audit liability		1,002,291		786,116
Clinical accrued liabilities		1,405,000		386,328
Manufacturing accrued liabilities		4,487,910		1,231,514
Pre-clinical accrued liabilities		99,000		398,468
Personnel related accruals		1,941,900		1,459,162
Other accrued liabilities		44,937		8,494

		8,981,038		4,270,082

Share-based payments (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of the Number and Weighted Average Exercise Prices Movements in Stock Options

Set out below is an overview of changes in the Stock Options and Restricted Stock Units (“RSUs”) during the six months ended June 30, 2022


	Stock Options					RSUs

	Outstanding options			Weighted average exercise price		Outstanding RSUs

Outstanding January 1, 2022		2,470,295		€	9.18		259,714
Granted		742,500		€	16.12		345,196
Exercised		(22,045	)	€	2.38		(5,190	)
Forfeited		—			—		(903	)

Outstanding June 30, 2022		3,190,750		€	10.84		598,817

Summary of Fair Value Per Option at Each Grant/Measurements Date Using the Black-Scholes Formula


	June 1, 2022			April 1, 2022			January 1, 2022

Number of options		120,000			552,500			70,000
Fair value of the options	€	11.83		€	11.50		€	9.10
Fair value of the ordinary shares	€	16.78		€	16.41		€	12.67
Exercise price	€	16.78		€	16.41		€	12.67
Expected volatility (%)		80	%		80	%		85	%
Expected life (years)		6.1			6.1			6.1
Risk-free interest rate (%)		3.0	%		2.6	%		1.4	%
Expected dividend yield		—			—			—

Basic and diluted loss per share (Tables)

6 Months Ended

Jun. 30, 2022

Text Block [Abstract]

Summary of Earnings Per Share


	For the three months ended June 30,						For the six months ended June 30,

	2022			2021 (*)			2022			2021 (*)

	€			€			€			€
Loss attributable to equity holders of the Company		(12,710,159	)		(15,202,347	)		(28,728,509	)		(21,243,974	)
Weighted average number of ordinary shares outstanding		33,582,171			33,126,351			33,368,220			27,646,066
Basic and diluted loss per share		(0.38	)		(0.46	)		(0.86	)		(0.77	)

(*) This has been revised. Refer to Note 2.1.

Related parties (Tables)

6 Months Ended

Jun. 30, 2022

Disclosure of transactions between related parties [abstract]

Summary of Compensation to Key Management Personnel

Key management personnel compensation


	For the three months ended June 30,				For the six months ended June 30,

	2022		2021		2022		2021

	€		€		€		€
Short term employee benefits		771,241		894,878		1,520,406		1,436,106
Post employee benefits		33,177		6,622		78,559		22,099
Share-based payments		954,796		825,074		2,175,098		2,122,736

Total		1,759,214		1,726,574		3,774,063		3,580,941

Corporate and Group information - Summary of Subsidiaries (Detail)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Pharvaris Holdings Bv Member
Disclosure Of Significant Investments In Subsidiaries Line Items
Name	Pharvaris Holdings B.V.
Legal seat	Leiden
Country of incorporation	The Netherlands
% of equity interest	100.00%	100.00%
Pharvaris Netherlands Bv Member
Disclosure Of Significant Investments In Subsidiaries Line Items
Name	Pharvaris Netherlands B.V.
Legal seat	Leiden
Country of incorporation	The Netherlands
% of equity interest	100.00%	100.00%
Pharvaris GmbH Member
Disclosure Of Significant Investments In Subsidiaries Line Items
Name	Pharvaris GmbH
Legal seat	Zug
Country of incorporation	Switzerland
% of equity interest	100.00%	100.00%
Pharvaris Inc Member
Disclosure Of Significant Investments In Subsidiaries Line Items
Name	Pharvaris, Inc.
Legal seat	Delaware
Country of incorporation	United States of America
% of equity interest	100.00%	100.00%

Corporate and Group information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2022
Corporate And Group Information Line Items
Entity incorporation, date of incorporation	Sep. 30, 2015

Summary of significant accounting policies - Additional Information (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Disclosure Of Significant Accounting Policies Line Items
Cash	€ 201,400,000		€ 201,400,000		€ 209,400,000
Cash flows from (used in) operations			(31,600,000)	€ (22,100,000)
Net loss	€ (12,621,068)	€ (15,202,773)	€ (28,648,098)	€ (21,245,649)

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2021-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2021-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2021-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2021-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2021-03-24

+ Details

Summary of significant accounting policies - Summary of detailed information of net loss and average weighted number of shares (Detail) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Q1 2021 [member] \| Previously stated [member]
Earnings per share [line items]
Weighted average number of shares	9,104,630	9,104,630
Q1 2021 [member] \| Revision [Member]
Earnings per share [line items]
Weighted average number of shares	22,104,888	22,104,888
Q2 2021 [member] \| Previously stated [member]
Earnings per share [line items]
Weighted average number of shares	16,154,350	16,154,350
Q2 2021 [member] \| Revision [Member]
Earnings per share [line items]
Weighted average number of shares	33,126,351	27,646,066
Q3 2021 [member] \| Previously stated [member]
Earnings per share [line items]
Weighted average number of shares	23,282,105	23,282,105
Q3 2021 [member] \| Revision [Member]
Earnings per share [line items]
Weighted average number of shares	33,128,593	29,493,657
Q1 2022 [member] \| Previously stated [member]
Earnings per share [line items]
Weighted average number of shares	33,135,821	33,135,821
Q1 2022 [member] \| Revision [Member]
Earnings per share [line items]
Weighted average number of shares	33,151,892	33,151,892

Summary of significant accounting policies - Summary of prior period adjustment of earnings per share (Detail) - € / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings per share [line items]
Basic and diluted loss per share	€ (0.38)	€ (0.46)	€ (0.86)	€ (0.77)
Q1 2021 [member]
Earnings per share [line items]
Basic and diluted loss per share	(0.66)		(0.66)
Q2 2021 [member]
Earnings per share [line items]
Basic and diluted loss per share	(0.94)		(1.32)
Q3 2021 [member]
Earnings per share [line items]
Basic and diluted loss per share	(0.39)		(1.31)
Q1 2022 [member]
Earnings per share [line items]
Basic and diluted loss per share	(0.48)		(0.48)
Revision [member] \| Q1 2021 [member]
Earnings per share [line items]
Basic and diluted loss per share	(0.27)		(0.27)
Revision [member] \| Q2 2021 [member]
Earnings per share [line items]
Basic and diluted loss per share	(0.46)		(0.77)
Revision [member] \| Q3 2021 [member]
Earnings per share [line items]
Basic and diluted loss per share	(0.28)		(1.03)
Revision [member] \| Q1 2022 [member]
Earnings per share [line items]
Basic and diluted loss per share	€ (0.48)		€ (0.48)

Research and development expenses - Breakdown of Research and Development Expenses (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	€ (13,721,637)	€ (8,060,599)	€ (27,236,126)	€ (16,132,053)
Personnel expenses Member
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	(3,061,036)	(1,759,669)	(5,590,207)	(3,768,165)
Clinical expenses Member
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	(7,175,545)	(3,496,223)	(13,741,610)	(6,761,928)
Nonclinical expenses Member
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	(1,016,793)	(1,181,660)	(1,832,918)	(2,143,713)
Manufacturing costs Member
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	(2,419,143)	(1,601,980)	(5,883,668)	(2,920,172)
License costs Member
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	0	0	0	(500,000)
Intellectual Property costs Member
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	€ (49,120)	€ (21,067)	€ (187,723)	€ (38,075)

Research and development expenses - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2022 EUR (€)
Analyti Con [Member] \| Phase2 Development [Member]
Statement [Line Items]
License costs consist milestone payment	€ 500,000

General and administrative expenses - Breakdown of General and Administrative Expenses (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Detailed Information General And Administrative Expenses [Abstract]
Personnel expenses (Note 5)	€ (3,825,151)	€ (1,795,721)	€ (6,270,034)	€ (3,036,786)
Consulting fees	(254,899)	(161,559)	(432,811)	(390,872)
Professional fees	(911,170)	(324,793)	(1,795,170)	(1,132,706)
Accounting, tax and auditing fees	(290,159)	(648,626)	(594,657)	(1,086,756)
Travel expenses	(260,446)	(2,563)	(404,200)	(3,357)
Facilities, communication & office expenses	(1,618,732)	(1,510,566)	(3,246,830)	(2,462,147)
Other expenses	(499,576)	(220,898)	(781,436)	(323,791)
Total	€ (7,660,133)	€ (4,664,726)	€ (13,525,138)	€ (8,436,415)

General and administrative expenses - Additional Information (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Detailed Information General And Administrative Expenses [Abstract]
Depreciation expense	€ 35,345	€ 11,987	€ 68,195	€ 15,048

Personnel expenses - Summary of Personnel Expenses (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Expenses By Nature [Abstract]
Wages and salaries	€ (3,279,593)	€ (1,606,969)	€ (5,845,176)	€ (2,618,645)
Pension charges	(177,185)	(51,327)	(355,729)	(81,289)
Other social security charges	(286,570)	(124,356)	(569,559)	(235,669)
Share-based payments	(3,142,839)	(1,772,738)	(5,089,777)	(3,869,348)
Total	€ (6,886,187)	€ (3,555,390)	€ (11,860,241)	€ (6,804,951)

Personnel expenses - Additional Information (Detail) - staff	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Expenses By Nature [Abstract]
Number of employees	47	17

Finance income/(expense) - Summary of Financial Expenses (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Financial Expenses [Abstract]
Foreign exchange differences	€ 11,535,811	€ (2,401,910)	€ 14,971,998	€ 3,503,986
Interest expenses over bank balances	(33,457)	(69,552)	(78,517)	(151,764)
Other finance expenses	(550)	(3,021)	(499)	(7,849)
Total finance (expenses)/income	€ 11,501,804	€ (2,474,483)	€ 14,892,983	€ 3,344,373

Income taxes - Summary of Income Tax Expense (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Major components of tax expense (income) [abstract]
Income tax expense	€ (2,741,102)	€ (2,965)	€ (2,779,817)	€ (21,554)
Total	€ (2,741,102)	€ (2,965)	€ (2,779,817)	€ (21,554)

- Definition

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]

+ References + Details

Income taxes - Summary of Reconciliation of Income Tax Benefit And The Accounting Loss (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Income/(loss) before tax	€ (9,879,966)	€ (15,199,807)	€ (25,868,281)	€ (21,224,095)
Income tax at statutory income tax rate in The Netherlands (25.8%)	2,549,031	3,799,952	6,674,016	5,306,024
Effect of tax rates in other countries	(3,211,414)	(1,160,468)	(6,017,458)	(3,171,956)
Temporary differences for which no deferred tax assets/liabilities have been recognized	0	(184,629)	0	(162,580)
Nondeductible expenses	(84,694)	(96,125)	(190,060)	(587)
Current period losses for which no deferred tax asset has been recognized	(1,994,025)	(2,361,695)	(3,246,315)	(1,992,455)
Income tax benefit	€ (2,741,102)	€ (2,965)	€ (2,779,817)	€ (21,554)

Income taxes - Summary of Reconciliation of Income Tax Benefit And The Accounting Loss (Parenthetical) (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
NETHERLANDS
Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate [Line Items]
Applicable tax rate	25.80%	25.80%	25.80%	25.80%

Income taxes - Additional Information (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate [Line Items]
Effective tax rate			10.70%	0.10%
Tax expense (income)	€ 2,741,102	€ 2,965	€ 2,779,817	€ 21,554
Accounting profit	€ (9,879,966)	€ (15,199,807)	(25,868,281)	(21,224,095)
Profit (loss) before tax			(25,868,281)	€ (21,224,095)
Dutch tax law [member]
Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate [Line Items]
Tax expense (income)			2,700,000
Accounting profit			17,400,000
Taxable income set off by utilization of accumulated losses carry forward			7,000,000
Profit (loss) before tax			€ 10,400,000

- Definition

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]

+ References + Details

Property, plant and equipment - Summary of Property, Plant and Equipment (Detail) - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Disclosure Of Property Plant And Equipment [Line Items]
Opening balance	€ 108,099
Additions	49,739	€ 78,251
Closing balance	141,846	108,099
Office equipment [member]
Disclosure Of Property Plant And Equipment [Line Items]
Opening balance	108,099
Additions	49,739
Depreciation expenses	(15,992)
Closing balance	141,846	€ 108,099
Cumulative depreciation [member] \| Office equipment [member]
Disclosure Of Property Plant And Equipment [Line Items]
Closing balance	(42,597)
Cumulative Costs [member] \| Office equipment [member]
Disclosure Of Property Plant And Equipment [Line Items]
Closing balance	€ 184,443

Property, plant and equipment - Additional Information (Detail) - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [abstract]
Acquired assets	€ 49,739	€ 78,251

Leases - Summary of information about right of use assets (Detail) - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Disclosure Of Leases [Abstract]
Balance at January 1	€ 243,250	€ 0
Addition		301,965
Depreciation charges	(52,203)	(58,715)
Impact of transaction of foreign currency	19,667
Balance at June 30, 2021	€ 210,714	€ 243,250

Leases - Summary of information about lease lease liabilities (Detail) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Disclosure Of Lease Liabilities [Line Items]
Lease liabilities	€ (212,865)	€ (250,184)
Current portion	(110,772)	(99,432)
Non-current portion	(102,093)	(150,752)
Office Lease [Member]
Disclosure Of Lease Liabilities [Line Items]
Lease liabilities	€ (212,865)	€ (250,184)

Leases - Additional Information (Detail) - EUR (€)	6 Months Ended
Leases - Additional Information (Detail) - EUR (€)	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Leases [Abstract]
Lease Agreement Term	3 years
Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16	3.12%	1.50%
Cash outflow for leases	€ 38,428	€ 5,012

Receivables - Summary of Receivables (Detail) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Text Block [Abstract]
Trade Receivables	€ 7,920	€ 8,451
VAT receivables	324,008	691,628
Total	€ 331,928	€ 700,079

Other current assets - Summary of Other Current Assets (Detail) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Text Block [Abstract]
Prepayments	€ 3,991,672	€ 1,507,753
Other assets	583,895	5,699
Total	€ 4,575,567	€ 1,513,452

Equity - Summary of Share Capital (Detail) - shares	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Feb. 05, 2021
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid	33,765,967	33,151,881	33,151,881
Ordinary shares [member]
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid	33,765,967	33,151,881		9,511,075

Equity - Additional Information (Detail)	3 Months Ended	6 Months Ended
Equity - Additional Information (Detail)	Mar. 31, 2022 USD ($)	Jun. 30, 2022 EUR (€) € / shares shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 EUR (€) shares	Dec. 31, 2021 EUR (€) shares	Feb. 05, 2021 € / shares shares	Feb. 04, 2021 € / shares
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid \| shares		33,765,967		33,151,881	33,151,881
Nominal value per share \| € / shares		€ 0.12
Voting rights description		one vote per share	one vote per share
Sale of ordinary share		€ 9,535,473		€ 157,155,899
Payments for share issue costs		727,308		12,925,547
Authorized share capital		14,100,000
Share capital		4,051,916		€ 3,975,432	€ 3,978,226
S V B Leerink [Member]
Disclosure of classes of share capital [line items]
Proceeds from issue of ordinary shares		9,200,000	$ 9,698,504
Payments for share issue costs		€ 308,000	$ 299,954
Ordinary shares [member]
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid \| shares		33,765,967			33,151,881	9,511,075
Nominal value per share \| € / shares						€ 0.12	€ 0.01
Number of shares authorized \| shares		58,750,000
Ordinary shares [member] \| S V B Leerink [Member]
Disclosure of classes of share capital [line items]
At-the-market program providing for sales from time to time \| $	$ 75,000,000
Sale of ordinary share		€ 588,100
Preference shares [member]
Disclosure of classes of share capital [line items]
Number of shares authorized \| shares		58,750,000

Trade and other payables - Summary of Trade and Other Liabilities (Detail) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Text Block [Abstract]
Trade payables	€ 3,681,792	€ 2,125,511
Tax and social security liabilities	487,163	365,061
Total Trade And Other Payables	€ 4,168,955	€ 2,490,572

Accrued liabilities - Summary of Accrued Liabilities (Detail) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Disclosure of financial liabilities [line items]
Accrued liabilities	€ 8,981,038	€ 4,270,082
Consulting, professional and audit liability[Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	1,002,291	786,116
Clinical accrued liabilities [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	1,405,000	386,328
Manufacturing accrued liabilities [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	4,487,910	1,231,514
Pre-clinical accrued liabilities [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	99,000	398,468
Personnel related accruals [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	1,941,900	1,459,162
Other accrued liabilities [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	€ 44,937	€ 8,494

Share-based payments - Summary of the Number and Weighted Average Exercise Prices Movements in Stock Options (Detail)	6 Months Ended
	Jun. 30, 2022 shares € / shares
Restricted Stock Units [Member]
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items]
Beginning balance	259,714
Granted	345,196
Exercised	(5,190)
Forfeited	(903)
Ending balance	598,817
Stock Options [Member]
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items]
Beginning balance	2,470,295
Granted	742,500
Exercised	(22,045)
Forfeited	0
Ending balance	3,190,750
Beginning balance, Weighted average \| € / shares	€ 9.18
Granted , Weighted average \| € / shares	16.12
Exercised , Weighted average \| € / shares	2.38
Forfeited , Weighted average \| € / shares	0
Ending balance , Weighted average \| € / shares	€ 10.84

Share-based payments - Summary of Fair Value Per Option at Each Grant/Measurements Date Using the Black-Scholes Formula (Detail)	Jun. 01, 2022 shares yr € / shares	Jun. 01, 2022 shares yr € / shares $ / shares	May 02, 2022 $ / shares	Apr. 01, 2022 shares yr € / shares	Apr. 01, 2022 shares yr € / shares $ / shares	Mar. 01, 2022 $ / shares	Feb. 01, 2022 $ / shares	Jan. 03, 2022 $ / shares	Jan. 01, 2022 shares yr € / shares	Jan. 01, 2022 shares yr € / shares $ / shares
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Exercise price \| $ / shares		$ 17.98	$ 17.1		$ 18.14	$ 18.47	$ 17	$ 16.41		$ 14.39
Black-Scholes formula [member]
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Number of options \| shares	120,000	120,000		552,500	552,500				70,000	70,000
Fair value of the options	€ 11.83	$ 11.83		€ 11.5	$ 11.5				€ 9.1	$ 9.1
Fair value of the ordinary shares	16.78	$ 16.78		16.41	$ 16.41				12.67	$ 12.67
Exercise price	€ 16.78			€ 16.41					€ 12.67
Expected volatility	80.00%	80.00%		80.00%	80.00%				85.00%	85.00%
Expected life \| yr	6.1	6.1		6.1	6.1				6.1	6.1
Risk-free interest rate	3.00%	3.00%		2.60%	2.60%				1.40%	1.40%
Expected dividend yield	0.00%	0.00%		0.00%	0.00%				0.00%	0.00%

Share-based Payments - Additional Information (Detail)								3 Months Ended		6 Months Ended
Share-based Payments - Additional Information (Detail)	Jun. 01, 2022 shares $ / shares	May 02, 2022 $ / shares	Apr. 01, 2022 shares $ / shares	Mar. 01, 2022 $ / shares	Feb. 01, 2022 $ / shares	Jan. 03, 2022 $ / shares	Jan. 01, 2022 shares $ / shares	Jun. 30, 2022 EUR (€) shares	Jun. 30, 2021 EUR (€) shares	Jun. 30, 2022 EUR (€) shares	Jun. 30, 2021 EUR (€) shares
statement of Lineitems [Line Items]
Number Of Instruments Granted InShare based Payment Arrangement	120,000		552,500				70,000
Weighted average share price \| $ / shares	$ 17.98	$ 17.1	$ 18.14	$ 18.47	$ 17	$ 16.41	$ 14.39
Description of maximum term of options granted for share-based payment arrangement	May 31, 2032		March 31, 2032				December 31, 2031
Percentage of aggregate number of stock options shall vest on one year at grant date	25.00%		25.00%				25.00%
Percentage of aggregate number of stock options shall vest on One Month at grant date	48.00%		48.00%				48.00%
Number of share options exercisable in share-based payment arrangement								1,287,099	337,667	1,287,099	337,667
Expense from share-based payment transactions \| €								€ 3,142,839	€ 1,772,738	€ 5,089,777	€ 3,869,347
Key management personnel of entity or parent [member]
statement of Lineitems [Line Items]
Weighted average share price \| $ / shares	$ 17.98
Employees [Member] \| Restricted Stock Units [Member]
statement of Lineitems [Line Items]
Number Of Instruments Granted InShare based Payment Arrangement										345,196

Basic and diluted loss per share - Summary of Earnings Per Share (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings per share [line items]
Loss attributable to equity holders of the Company	€ (12,710,159)	€ (15,202,347)	€ (28,728,509)	€ (21,243,974)
Weighted average number of ordinary shares outstanding	33,582,171	33,126,351	33,368,220	27,646,066
Basic earnings loss per share	€ (0.38)	€ (0.46)	€ (0.86)	€ (0.77)
Diluted earnings loss per share	€ (0.38)	€ (0.46)	€ (0.86)	€ (0.77)

Commitments and Contingencies - Additional Information (Detail) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Disclosure of other provisions [abstract]
Contingent liabilities	€ 0		€ 0
Contingent assets	0		€ 0
Material claims known to management related to the activities of the group	0
Contractual obligations and commitments	€ 16,000,000	€ 19,500,000

Related parties - Summary of Compensation to Key Management Personnel (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure of transactions between related parties [abstract]
Short term employee benefits	€ 771,241	€ 894,878	€ 1,520,406	€ 1,436,106
Post employee benefits	33,177	6,622	78,559	22,099
Share-based payments	954,796	825,074	2,175,098	2,122,736
Total	€ 1,759,214	€ 1,726,574	€ 3,774,063	€ 3,580,941

Related parties - Additional information (Detail)	6 Months Ended
Related parties - Additional information (Detail)	Jun. 30, 2022 EUR (€) shares	Jun. 30, 2021 EUR (€)	Dec. 31, 2021 EUR (€)
Stock Options [Member]
Disclosure Of Information About Key Management Personnel [Line Items]
Number of share options granted in share-based payment arrangement	742,500
Restricted Stock Units [Member]
Disclosure Of Information About Key Management Personnel [Line Items]
Number of share options granted in share-based payment arrangement	345,196
Key management personnel of entity or parent [member]
Disclosure Of Information About Key Management Personnel [Line Items]
Amount of outstanding payable \| €	€ 417,760		€ 1,157,029
Amount incurred by entity for provision of key management personnel services provided by separate management entity \| €	€ 538,744	€ 974,125
Key management personnel of entity or parent [member] \| Stock Options [Member]
Disclosure Of Information About Key Management Personnel [Line Items]
Number of share options granted in share-based payment arrangement	445,000
Key management personnel of entity or parent [member] \| Restricted Stock Units [Member]
Disclosure Of Information About Key Management Personnel [Line Items]
Number of share options granted in share-based payment arrangement	14,216